ArticleInternational journal of laboratory hematology2026
Point-Of-Care Testing of Fibrinogen by the qLab FIB System in Patients Taking Direct Oral Anticoagulants (DOACs).
Article in International journal of laboratory hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionFibrinogen deficiency is common in acute haemorrhage and requires prompt treatment to prevent exacerbation of coagulopathy. Conventional lab measurements are time consuming, leading to delayed intervention or empirical fibrinogen replacement, potentially exposing patients to unnecessary transfusion. The qLabs FIB system offers rapid point-of-care measurement of fibrinogen at the bedside; however, its use in patients taking Direct Oral Anticoagulants (DOACs) has not been evaluated.
methodsThirty patients chronically anticoagulated with Apixaban or Edoxaban undergoing catheter ablation procedures for atrial fibrillation were recruited. Citrated blood samples were taken from each patient and assessed using the qLab FIB system, and lab-based Clauss assay (HemosIL Q.F.A. Thrombin (QFA), Werfen, Bedford, USA). DOAC levels were also measured, then removed using DOAC-Remove (Quadratech, UK) to assess their impact. Statistical analysis was performed using Bland-Altman, Passing-Bablok regression and paired t-tests.
resultsA strong linear correlation (r = 0.88) was observed between the two methods; however, the qLabs FIB system consistently overestimated fibrinogen levels compared to the Clauss assay, with a mean bias of +0.50 g/L (95% LOA: -0.03 to +1.02 g/L). The Passing-Bablok slope of 0.64 suggested that overestimation might be more pronounced at lower fibrinogen concentrations. DOAC presence did not significantly alter measurement results (p = 0.380), and DOAC concentration did not correlate with the measurement discrepancy.
conclusionThe qLabs FIB system is a viable method for rapid assessment of fibrinogen levels in patients anticoagulated with DOACs. However, the presence of overestimation bias may have implications for clinical decision making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.